Byetta Pen Pancreatitis Concerns Cause Amylin Stock to Fall

Over the eight weeks since concerns first emerged about a potential link between the Byetta pen and pancreatitis, the stock price for the drug’s maker, Amylin Pharmaceuticals, has fallen dramatically.

 
Byetta (exenatide) is a drug approved for treatment of Type 2 diabetes, which has been used by nearly one million people since it was approved in 2005. It is a twice daily injection which is sold in a pre-filled pen by Amylin Pharmaceuticals and Eli Lilly & Co.

On August 18, 2008, the FDA issued a warning to healthcare providers about 6 severe cases of pancreatitis among Byetta users. Prior FDA reports had indicated that at least 30 users had developed acute pancreatitis while using Byetta, but these 6 cases involved necrotizing pancreatitis and hemorrhagic pancreatitis, which resulted in at least 2 deaths.

Did You Know?

Millions of Philips CPAP Machines Recalled

Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.

Learn More

Although the FDA has not reached any firm conclusions about whether Byetta side effects cause pancreatitis, these reports raised substantial concern among the medical community, diabetics and investors. The day of the announcement, the stock price for Amylin Pharmaceuticals, which is heavily dependent on sales of Byetta, dropped nearly 20%, from $35 per share to $28.10.

On August 25, 2008, Eli Lilly and Amylin held a conference call with investors and the public in an attempt to ease concerns about the potential Byetta pen pancreatitis risk. Although the manufacturers denied that the evidence supports a connection between Byetta side effects and pancreatitis, they disclosed that they were aware of at least four other deaths among users of the drug caused by severe cases of pancreatitis.

At the close of the market today, Amylin shares traded at $12.40, which is only about one-third what they were worth two months ago.

Analysts expect the third-quarter sales for the Byetta pen to be well below original estimates and the pending approval of a longer-acting version of Byetta could be delayed until 2011 as a result of the concerns about the association with pancreatitis.

At least one Byetta pancreatitis lawsuit has already been filed by a user of the drug. The case was filed in California State Court on August 20, 2008 alleging that Amylin and Eli Lilly failed to adequately test their product and did not properly warn about the serious and potentially life-threatening pancreatitis side effects.

Byetta lawyers throughout the country are reviewing and investigating additional cases, and many investors fear that Amylin could be facing one of the next big mass torts in the United States.

Image Credit: |

4 Comments

  • RosemaryMay 20, 2009 at 12:05 pm

    I have been in & out of the hospital from Oct. 20, 2008, till Jan. 12, 2009, with acute pancreatitis. I was on byetta for nearly 2 years. My gall bladder was removed, I needed a feeding tube thru the nose, due to a large cyst that developed on my pancreas, squeezing my stomach. Cyst doubled in size, needed a procedure to drain it into my small intestine. I am now dealing with a nearly daily[Show More]I have been in & out of the hospital from Oct. 20, 2008, till Jan. 12, 2009, with acute pancreatitis. I was on byetta for nearly 2 years. My gall bladder was removed, I needed a feeding tube thru the nose, due to a large cyst that developed on my pancreas, squeezing my stomach. Cyst doubled in size, needed a procedure to drain it into my small intestine. I am now dealing with a nearly daily bloody nose, which I think has been caused during removal of feeding tube.

  • Byetta Pancreatitis Problems Cause Sales and Amylin Stock to Fall : AboutLawsuits.comJanuary 29, 2009 at 6:29 pm

    [...] about a possible association between Byetta and pancreatitis caused a number of patients and doctors move away from the drug in the second half of last year, [...]

  • FDA Requires Additional Byetta Safety Data Before Considering Long-Acting Version : AboutLawsuits.comNovember 5, 2008 at 5:17 pm

    [...] Amylin Pharmaceutical’s stock price began falling sharply in August, when concerns emerged about potentially fatal Byetta pen pancreatitis side effects. [...]

  • DJOctober 17, 2008 at 4:52 pm

    I am currently taking Byetta with no issues, side effects, etc. I've lost 8lbs on this medication & it's lowered my blood sugar significantly. It's the best I've felt in over a year. I suspect each severe case had other health issues going on that caused their problems, not simply the Byetta itself.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Gardasil Lawsuits Over Failure To Warn Doctors About HPV Vaccine Risks Cleared To Move Forward
Gardasil Lawsuits Over Failure To Warn Doctors About HPV Vaccine Risks Cleared To Move Forward (Posted today)

A federal judge has cleared Gardasil lawsuits to move forward, after paring down plaintiffs' claims to those alleging Merck either failed to warn, or fraudulently concealed, the HPV vaccine's risks from the medical community.